Clinical trial
Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients…
NCT00128544 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00128544 |
|---|---|
| Title | Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B |
| Official title | A Randomized, Blinded, Phase IIb Trial of Telbivudine (LdT) Versus the Combination of Telbivudine and Valtorcitabine (Val-LdC) in Patients With Chronic Hepatitis B |
| Lead sponsor | Novartis, Industry |
| Collaborators | Novartis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Drug |
| Interventions | telbivudine, valtorcitabine |
| Enrollment | 130 |
| Start date | May 1, 2005 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Aug 10, 2005 |
| Last update posted | Jun 16, 2017 |
| Countries | Hong Kong, New Zealand, Singapore |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: